Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Verastem Expression of Interest Call VS
Document related concepts
no text concepts found
Transcript
Verastem Expression of Interest Call VS-4718: FAK/PYK2 kinase inhibitor VS-4718, is an oral small molecule FAK/PYK2 kinase inhibitor. Verastem are interested to review expressions of interest with a strong scientific rational for novel combinations (including immune checkpoint inhibitors, other immunoâoncology agents and targeted agents of other classes). Of note, VS-4718 is able to cross the blood brain barrier, offering opportunity for Glioblastomas and other brain cancers. Please refer to the non-confidential data package for further information on VS- 4718. VS-5584: PI3K/mTOR kinase inhibitor VS-5584, is a small molecule PI3K/mTOR kinase inhibitor. Verastem are interested to review expressions of interest with a strong scientific rational for novel combinations and have expressed a particular interest in the following areas: - BTK inhibitor combination in lymphoma/leukemia (e.g. DLBCL) - Combination with cisplatin + XRT in cervical cancer - Combination with androgen receptor blockade in prostate cancer - Combination with platinum in BRCA mutant cancers (ovarian ca post PARPi, TNBC etc.) - Combination with weekly paclitaxel in endometrial cancer Please refer to the non-confidential data package for further information on VS- 5584.
